Literature DB >> 15549623

The pediatric cardiology pharmacopoeia: 2004 update.

S Barnes1, B Shields, W Bonney, J Hardin, R Abdulla.   

Abstract

Seven years ago, Pediatric Cardiology published the first version of a review article outlining the various medications used in the field of heart diseases in children. This article is an update and expansion to what we have previously presented. Therapeutic intervention, both surgical and through cardiac catheterization, has enabled cure and palliation of an increasingly expanding spectrum of diseases at earlier ages and with more complex lesions. Refinement of these procedures includes more advanced tools as well as the support of an expanding armament of pharmacopoeia used to stabilize and support patients before, during, and after such procedures. In addition to updating previously published data regarding inotropes, antiarrhythmics, vasodilators, diuretics, sedatives, and analgesics as well as a variety of miscellaneous medications, this article describes the use of pulmonary medications frequently needed in patients with congestive heart failure, pulmonary edema, and chronic lung disease. We also describe the difficult management of withdrawal as a result of use of sedatives and analgesics. The most recent recommendation for subacute bacterial endocarditis prophylactic antibiotic regimens is also described.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15549623     DOI: 10.1007/s00246-003-0692-z

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.838


  21 in total

Review 1.  Antithrombotic therapy in children.

Authors:  P Monagle; A D Michelson; E Bovill; M Andrew
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 2.  Inhaled alternatives to nitric oxide.

Authors:  Stuart M Lowson
Journal:  Anesthesiology       Date:  2002-06       Impact factor: 7.892

Review 3.  Prevention of bacterial endocarditis. Recommendations by the American Heart Association.

Authors:  A S Dajani; K A Taubert; W Wilson; A F Bolger; A Bayer; P Ferrieri; M H Gewitz; S T Shulman; S Nouri; J W Newburger; C Hutto; T J Pallasch; T W Gage; M E Levison; G Peter; G Zuccaro
Journal:  JAMA       Date:  1997-06-11       Impact factor: 56.272

4.  The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension.

Authors:  A Haraldsson s; N Kieler-Jensen; S E Ricksten
Journal:  Anesth Analg       Date:  2001-12       Impact factor: 5.108

5.  An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension.

Authors:  G Mikhail; J Gibbs; M Richardson; G Wright; A Khaghani; N Banner; M Yacoub
Journal:  Eur Heart J       Date:  1997-09       Impact factor: 29.983

6.  Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.

Authors:  M M Hoeper; M Schwarze; S Ehlerding; A Adler-Schuermeyer; E Spiekerkoetter; J Niedermeyer; M Hamm; H Fabel
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

7.  Vasodilator therapy for primary pulmonary hypertension in children.

Authors:  R J Barst; G Maislin; A P Fishman
Journal:  Circulation       Date:  1999-03-09       Impact factor: 29.690

8.  B-type natriuretic peptide in cardiovascular disease.

Authors:  James A de Lemos; Darren K McGuire; Mark H Drazner
Journal:  Lancet       Date:  2003-07-26       Impact factor: 79.321

9.  Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance.

Authors:  A Haraldsson; N Kieler-Jensen; U Nathorst-Westfelt; C H Bergh; S E Ricksten
Journal:  Chest       Date:  1998-09       Impact factor: 9.410

10.  Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.

Authors:  H Olschewski; D Walmrath; R Schermuly; A Ghofrani; F Grimminger; W Seeger
Journal:  Ann Intern Med       Date:  1996-05-01       Impact factor: 25.391

View more
  6 in total

Review 1.  The pediatric cardiology pharmacopeia: 2013 update.

Authors:  Paul Nicholas Severin; Sawsan Awad; Beth Shields; Joan Hoffman; William Bonney; Edmundo Cortez; Rani Ganesan; Aloka Patel; Steve Barnes; Sean Barnes; Shada Al-Anani; Umang Gupta; Yolandee Bell Cheddar; Ismael E Gonzalez; Kiran Mallula; Hani Ghawi; Suhaib Kazmouz; Salwa Gendi; Ra-id Abdulla
Journal:  Pediatr Cardiol       Date:  2012-11-29       Impact factor: 1.655

Review 2.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 3.  The management of hypertensive emergencies in children after stem cell transplantation.

Authors:  D G Horn; M N Trame; G Hempel
Journal:  Int J Clin Pharm       Date:  2011-03-12

4.  Evaluation by N-terminal prohormone of brain natriuretic peptide concentrations and ross scoring of the efficacy of digoxin in the treatment of heart failure secondary to congenital heart disease with left-to-right shunts.

Authors:  Ozlem Elkiran; Ayse Sandikkaya; Gulendam Kocak; Cemsit Karakurt; Cagatay Taskapan; Saim Yologlu
Journal:  Pediatr Cardiol       Date:  2013-03-13       Impact factor: 1.655

5.  Extemporaneous suspension of propafenone: attending lack of pediatric formulations in Mexico.

Authors:  Hugo Juárez Olguín; Carmen Flores Pérez; Blanca Ramírez Mendiola; Rafael Coria Jiménez; Eunice Sandoval Ramírez; Janett Flores Pérez
Journal:  Pediatr Cardiol       Date:  2008-06-28       Impact factor: 1.655

6.  Signalosomes as Therapeutic Targets.

Authors:  Alejandra Negro; Kimberly Dodge-Kafka; Michael S Kapiloff
Journal:  Prog Pediatr Cardiol       Date:  2008-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.